Aeolus Pharmaceuticals Inc.
23811 Inverness Place
Laguna Niguel,
CA 92677
United States - Map
Phone: 949-481-9825
Fax: 949-481-9829
Web Site: http://www.aeoluspharma.com
| Aeolus Pharmaceuticals, Inc., through its subsidiary, Aeolus Sciences, Inc., develops a class of catalytic antioxidant compounds for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Its target indications are as a protective agent against the effects of mustard gas exposure, radiation exposure and cancer radiation therapy, chlorine gas exposure, and amyotrophic lateral sclerosis, known as ALS or Lou Gehrigs disease. The companys lead drug candidate, AEOL 10150, is a small molecule catalytic antioxidant that can scavenge a range of reactive oxygen species or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the bodys natural enzymatic systems for eliminating these damaging compounds. Aeolus Pharmaceuticals product pipeline also includes AEOL 11207, AEOL 11203, and AEOL 11216. The company was founded in 1994 and is based in Mission Viejo, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John L. McManus , 44
Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Michael P. McManus , 39
Chief Financial Officer, Chief Accounting Officer, Sec. and Treasurer |
N/A
| N/A | Dr. Brian J. Day Ph.D, 49
Chief Scientific Officer |
N/A
| N/A | Mr. Clayton I. Duncan , 59
Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
